An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

KERENDIA®

Drug Information Related Patent

Hold Company

BAYER HLTHCARE

Learn More

Dosage and Administration

TABLET;ORAL

Specification

10MG; 20MG

Indication

KERENDIA® reduces the risk for sustained eGFR decline, end-stage renal disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) and type II diabetes mellitus (T2D).

Use

Instructions for Use

API

FINERENONE

API Structure